Article Text
Abstract
It has been hypothesised that the reimbursement system pertaining to radiotherapy is influencing prescription practices for patients with cancer with bone metastases. In this paper, we present and discuss the results of an empirical study that was undertaken on patient records, referred to radiotherapy for the treatment of bone metastases, in a medium-size city, in southern Brazil, during the period of March 2006 to March 2014. Our findings seem to confirm this hypothesis: after a change in the reimbursement method, radiation prescriptions were adapted accordingly, in order to maximise profits. Once such patients become highly vulnerable due to their diagnoses, they also become susceptible to a subtle form of exploitation; physicians let patients believe that more radiation will be better for their health, and they do so despite knowing otherwise, and as it seems, out of pecuniary interests.
- ethics
- nuclear power/radiation
- professional misconduct
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Geographical distance and reduced access to palliative radiotherapy: systematic review and meta-analysis
- Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?
- Retrospective analysis of characteristics associated with higher-value radiotherapy episodes of care for bone metastases in Medicare fee-for-service beneficiaries
- Managing metastatic bone pain
- Optimal dose-fractionation schedule of palliative radiotherapy for patients with bone metastases: a protocol for systematic review and network meta-analysis
- Managing skeletal related events resulting from bone metastases
- Radiation therapy in malignant spinal cord compression: what is the current knowledge on fractionation schedules? A systematic literature review
- Advances in radiotherapy
- Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma
- Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer